| 000 | 01821 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250518011345.0 | ||
| 264 | 0 | _c20200819 | |
| 008 | 202008s 0 0 eng d | ||
| 022 | _a2047-4881 | ||
| 024 | 7 |
_a10.1177/2047487318815967 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLaffin, Luke J | |
| 245 | 0 | 0 |
_aA data-zone scoring system to assess the generalizability of clinical trial results to individual patients. _h[electronic resource] |
| 260 |
_bEuropean journal of preventive cardiology _c04 2019 |
||
| 300 |
_a569-575 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aBlood Glucose _xmetabolism |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 | _aBody Mass Index |
| 650 | 0 | 4 |
_aCholesterol _xblood |
| 650 | 0 | 4 | _aClinical Decision-Making |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 |
_aCreatinine _xblood |
| 650 | 0 | 4 | _aEligibility Determination |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealth Status |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xdiagnosis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNutrition Surveys |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 700 | 1 | _aBesser, Stephanie A | |
| 700 | 1 | _aAlenghat, Francis J | |
| 773 | 0 |
_tEuropean journal of preventive cardiology _gvol. 26 _gno. 6 _gp. 569-575 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/2047487318815967 _zAvailable from publisher's website |
| 999 |
_c29091680 _d29091680 |
||